



Wound Care Innovations.

Empowering
Solutions.

Antimicrobial ECM

Bioengineered Living Cells

Placental Allografts

Antimicrobial ECM

Start with
PuraPly®
Antimicrobial
for all wound types

PuraPly®AM

Antimicrobial Wound Matrix

PuraPly®XT Extra Fenestrated

Five-layer Antimicrobial Wound Matrix

Puts you in immediate control of the healing environment

The advanced antimicrobial barriers help control
bioburden between weekly debridements¹⁻⁵

POWERFUL UNIQUE COMBINATION

- Native, cross-linked ECM + broad-spectrum PHMB acts as a bridge between weekly debridements by providing a sustained antimicrobial barrier effect¹⁻⁵

EARLY BIOBURDEN MANAGEMENT

- The PuraPly® Antimicrobial product line is the optimal foundation of care following sharp debridement to control bioburden and prevent biofilm re-formation⁶⁻⁸

SUPPORTS HEALING

- In real-world clinical studies, PuraPly® AM demonstrated a decrease in wound size, reduction in time to closure, and an increase in observed granulation tissue^{9,10}

ELIMINATES THE NEED FOR AT-HOME PRIMARY DRESSING CHANGES

- Patient adherence improves when treatments require less intervention¹¹

PRODUCT FEATURES

PuraPly®AM

Antimicrobial Wound Matrix

Two layers of native, cross-linked ECM¹

Expanding clinical evidence in a variety
of acute and chronic wounds^{9,10}

Multiple sizes available

PuraPly®XT Extra Fenestrated

Five-layer Antimicrobial Wound Matrix

Five layers of native, cross-linked ECM²

Thicker ECM maximizes surface area for
PHMB saturation^{2,7,13}

A higher number of fenestrations compared
to PuraPly AM^{1,2}



BRIDGE BETWEEN WEEKLY DEBRIDEMENT¹²



Bioengineered Living Cells


For stalled
VLUs and DFUs

Apligraf®

Living Cellular Skin Substitute

Innovation that remains ahead of its time

The biotech healer for stalled
venous leg ulcers (VLUs) and
diabetic foot ulcers (DFUs)



BIOENGINEERED WITH LIVING CELLS

- Apligraf® looks, functions, and responds like healthy human skin¹⁴⁻¹⁷
- The cells of Apligraf are bioactive and poised to heal^{15,18}

TRANSFORMS WOUNDS FROM CHRONIC TO ACUTE

- Apligraf activates the patient's cells and helps regulate and correct growth factor signaling^{19,20}
- Apligraf helps restore normal healing functions, putting wounds back on track to heal^{15,18,19,21}

BACKED BY UNMATCHED CLINICAL PROOF

- Extensive studies have demonstrated time and again Apligraf's ability to heal more VLUs and DFUs faster^{14,22-27}
- Only Apligraf has conducted randomized controlled trials (RCTs) resulting in FDA approval for VLUs and DFUs¹⁴

PROVEN TO BE COST-EFFECTIVE

- Helps to reduce VLU and DFU burden on patients and healthcare costs²⁸⁻³¹

UNSURPASSED ACCESS FOR PATIENTS

- 100% of Medicare contractors and commercial medical policies cover Apligraf treatment for VLUs and DFUs

APLIGRAF HEALED



Placental Allografts

For all stalled
wound types

Affinity[®]

Fresh Amniotic Membrane

Living cells. Fresh solution.

Affinity[®] is the only fresh amniotic membrane wound covering³²⁻³⁴ and has been shown to help move wounds from stalled to closed³⁵

CLOSEST CHOICE TO NATIVE AMNIOTIC MEMBRANE

- Affinity uses a gentle, proprietary process, AlloFresh™, that preserves the product in its fresh state and retains its native tissue characteristics^{32,33,36-38}

OPTIMAL TISSUE COMPOSITION

Never frozen or dehydrated, Affinity retains:

- Viable endogenous cells, including epithelial cells and fibroblasts^{33,36}
- Growth factors and cytokines^{33,39}
- Native extracellular matrix (ECM) proteins^{33,37,38}
- Spongy layer³³

CLINICAL DATA IN RANDOMIZED CONTROLLED TRIAL AND REAL-WORLD SETTINGS

- As a protective wound covering, Affinity has been shown to support healing in a variety of wound types^{35,40-42}

Note: Affinity is intended for use as a wound covering and barrier.



NuShield[®]

Sterilized, Dehydrated Placental Allograft

The most complete dehydrated placental allograft wound covering^{37,43}

Convenience without compromise to support an optimal environment for healing



COMPLETE LAYERS SET NuSHIELD APART

- NuShield[®] is a shelf-stable, dehydrated placental allograft wound covering that undergoes a unique preservation method and retains all layers of the placental membrane, including the spongy layer^{43,44}

RETAINS GROWTH FACTORS AND CYTOKINES^{43,45,46}

- Following processing, analytical testing identified 640 components (growth factors, cytokines, and chemokines) that are retained in NuShield⁴⁶

CLINICAL DATA

- As a protective wound covering and in real-world patients, NuShield has been shown to support a favorable environment for healing in a variety of wound types and sizes⁴⁷

Note: NuShield is intended for use as a wound covering and barrier.

Organogenesis

Empowering Healing

Addressing Wounds From Head to Toe With Innovative Solutions*

Native, Cross-linked
ECM + Broad-spectrum
PHMB Antimicrobial Barriers

PuraPly[®]AM

Antimicrobial Wound Matrix

PuraPly[®]XT
Extra Fenestrated

Five-layer Antimicrobial Wound Matrix

Fresh & Dehydrated
Placental Allograft
Wound Coverings

Affinity[®]

Fresh Amniotic Membrane

NuShield[®]

Sterilized, Dehydrated Placental Allograft



Bioengineered
Living Cells[†]

Apligraf[®]

Living Cellular Skin Substitute

* Organogenesis offers a variety of innovative products for wound care that are FDA PMA approved, 510(k) cleared, or are marketed under Section 361 of the Public Health Service Act as HCT/PS.

† Apligraf is approved for the treatment of VLU and DFU.

Organogenesis is a leader in wound healing and for over 20 years has provided innovative solutions to help empower clinicians.

www.organogenesis.com

Organogenesis' Circle of Care is a comprehensive program that provides the highest-quality customer service and reimbursement support, with a wide range of expertise that includes benefits verification, information on ordering and shipping, and details on coding.



References

1. PuraPly Antimicrobial [package insert]. Canton, MA: Organogenesis Inc; 2020.
2. PuraPly XT Extra Fenestrated [package insert]. Canton, MA: Organogenesis Inc.
3. Data on file. PDR-0001. Organogenesis Inc.
4. Data on file. PDR-0002. Organogenesis Inc.
5. Data on file. PDR-0003. Organogenesis Inc.
6. Hübner NO, et al. *Skin Pharmacol Physiol*. 2010;23(1 suppl):17-27.
7. Brantley J, et al. *Wounds Int*. 2016;7(3):1-5.
8. Gilbert P, et al. *J Appl Microbiol*. 2005;99(4):703-715.
9. Oropallo AR. *Plast Reconstr Surg Glob Open*. 2019;7:e2047.
10. Bain MA, et al. *Plast Reconstr Surg Glob Open*. 2019;7(6):e2251.
11. Atreja A, et al. *MedGenMed*. 2005;7(1):4.
12. Davis SC, et al. *Int Wound J*. 2021;1-14. <https://doi.org/10.1111/iwj.13600>.
13. Carpenter S, et al. *Wounds*. 2016;28(6 suppl):S1-S20.
14. Apligraf [package insert]. Canton, MA: Organogenesis Inc; 2017.
15. Milstone LM, et al. *Wounds*. 2000;12(5 suppl A):12A-19A.
16. Schmid P. *Wounds*. 2000;12(5 Suppl A):4A-11A.
17. Carlson M, et al. *Tissue Eng Part A*. 2011;17(3-4):487-493.
18. Falanga V, et al. *J Invest Dermatol*. 2002;119(3):653-660.
19. Stone RC, et al. *Sci Transl Med*. 2017;9(371).doi:10.1126/scitranslmed.aaf8611.
20. Stone RC, et al. *Wound Repair Regen*. 2020;28:164-176.
21. Brem H, et al. *Surg Technol Int*. 2003;11:23-31.
22. Marston WA, et al. *Wound Repair Regen*. 2014;22(3):334-340.
23. Treadwell T, et al. *Adv Wound Care*. 2018;7(3):69-76.
24. Sabolinski ML, et al. *J Comp Eff Res*. 2018;7(8):797-805.
25. Veves A, et al. *Diabetes Care*. 2001;24(2):290-295.
26. Kirsner RS, et al. *Wound Repair Regen*. 2015;23(5):737-744.
27. Data on file. Organogenesis Inc.
28. Rice JB, et al. *J Med Econ*. 2014;17(5):347-356.
29. Barshes NR, et al. *Diabet Foot Ankle*. 2013;4.doi:10.3402/dfa.v4i0.21847.
30. Schonfeld WH, et al. *Wound Repair Regen*. 2000;8(4):251-257.
31. Rice JB, et al. *J Med Econ*. 2015;18(8):586-595.
32. Data on file. DR-0005. Organogenesis Inc.
33. McQuilling JP, et al. *Int Wound J*. 2017;14(6):993-1005.
34. Affinity Allograft Tissue Information and Instructions for Use. Canton, MA: Organogenesis Inc; 2021.
35. Serena TE, et al. *J Comp Eff Res*. 2020;9(1):23-34.
36. Data on file. DR-0008. Organogenesis Inc.
37. Niknejad H, et al. *Eur Cells Mater*. 2008;15:88-99.
38. Mamede AC, et al. *Cell Tissue Res*. 2012;349(2):447-458.
39. Data on file. DR-0007. Organogenesis Inc.
40. Sabo M, et al. *Chronic Wound Care Manage Res*. 2018;5:1-4.
41. Lambert CJ, et al. Poster presented at: Symposium on Advanced Wound Care Fall 2015; September 26-28, 2015; Las Vegas, NV.
42. Carpenter S, et al. Poster presented at: 4th Annual Innovations in Wound Healing Conference; December 7-10, 2017; Bimini, Bahamas.
43. McQuilling JP, et al. *Int Wound J*. 2019;16(3):827-840.
44. Data on file. Description of BioLoc Process. Organogenesis Inc.
45. Data on file. DR-0004. Organogenesis Inc.
46. McQuilling JP, et al. *Wound Repair Regen*. 2019;27(6):609-621.
47. Caporusso J, et al. *Wounds*. 2019;31(4 Suppl):S19-S27.